First Affiliated Hospital of Fujian Medical University
福建医科大学附属第一医院
Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Affiliated Hospital of Fujian Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌17 papers led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
- Hepatocellular carcinoma肝细胞癌59 papers led
- Stomach cancer胃癌38 papers led1 open trial led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Osteosarcoma骨肉瘤13 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
- Neuroblastoma神经母细胞瘤5 papers led
- Multiple myeloma多发性骨髓瘤15 papers led1 open trial led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病4 papers led
- Myasthenia gravis重症肌无力2 papers led
- Wilson disease肝豆状核变性(Wilson 病)3 papers led1 open trial led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症6 papers led1 open trial led
- Spinal muscular atrophy脊髓性肌萎缩症0 papers led1 open trial led
- Duchenne muscular dystrophy杜氏肌营养不良5 papers led1 open trial led
- Behçet disease白塞病2 papers led
- IgA nephropathyIgA 肾病3 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
- Hirschsprung disease先天性巨结肠2 papers led
- Hereditary angioedema遗传性血管性水肿0 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led
Not listed for: Hepatoblastoma, Chordoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 17 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.7%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Fuzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led17
- LncRNA ZNF295-AS1 modulates nasopharyngeal carcinoma progression via the miR-762/HDAC6 axis-mediated autophagy.
- Deformable registration for nasopharyngeal carcinoma using adaptive mask and weight allocation strategy based CycleFCNs model.
- Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.
- VMAT with CCC Algorithm Optimizes Trismus Prevention: Dose-Response Analysis of Jaw Muscles Dmean and Dmax in T3-T4 Nasopharyngeal Carcinoma.
- Radiation-induced nasopharyngeal ulcers after re-irradiation with intensity-modulated radiotherapy in locoregional recurrent nasopharyngeal carcinoma patients: a dose-volume-outcome analysis.
- A head-to-head comparison of [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study.
- Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.
- The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.
- Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.
- The effect of early oral nutritional supplements on improving nutritional outcomes and radiation-induced oral mucositis for nasopharyngeal carcinoma patients undergoing concurrent chemoradiotherapy.
- Effect of nutritional status before radiotherapy on radiation-induced acute toxicities in patients with nasopharyngeal carcinoma.
- Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.
- The psychological status in patients with nasopharyngeal carcinoma during radiotherapy.
- [68Ga]Ga-FAPI PET/CT Improves the T Staging of Patients with Newly Diagnosed Nasopharyngeal Carcinoma: A Comparison with [18F]F-FDG.
- Prognostic models for 1-year survival of NPC after radiotherapy in different ages.
- Anxiety and depression status prior to radiotherapy in patients with nasopharyngeal carcinoma and its effect on acute radiation toxicities.
- The effect of psychological condition before radiotherapy on prognosis in 390 patients initially treated for nasopharyngeal carcinoma.
All its trials on ClinicalTrials.gov, any status4
- A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
- Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images
- Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
More papers found outside PubMed (not counted)6
- LBA103 Early versus routine oral nutritional supplements during concurrent chemoradiotherapy for nasopharyngeal carcinoma: Efficacy and cost-utility analysis in a multicenter randomized controlled trial
- Multicenter dosimetric consistency evaluation of IMRT and VMAT techniques based on AAPM TG119 Report and clinical cases
- Signal “off-on” electrochemical aptamer sensing of interleukin-6 based on platinum nanoparticles/MIL-88B MOF nanozyme
- Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
- Identifying immune cell infiltration and diagnostic biomarkers for nasopharyngeal carcinoma through bioinformatic analysis
- General Introduction of PET/CT of Nasopharyngeal Carcinoma
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Fuzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Phase
- Phase 3
- Started
- 2025-03
- Registry
- NCT06644781
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China.
- First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.
- LncRNA NRON negatively regulates cisplatin-induced cell apoptosis via downregulating miR-31 in esophageal squamous cell carcinomas.
All its trials on ClinicalTrials.gov, any status5
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)11
- CircSLC7A5 upregulates NRD1 by competing with miR-148a-3p to promote progression of esophageal squamous cell carcinoma
- Agaricus blazei murrill and Enteromorpha prolifera-derived polysaccharides gain therapeutic effects on esophageal squamous cell carcinoma
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Targeting UNC-51-like kinase 1 can inhibit esophageal cancer cell proliferation and regulate autophagy
- Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma
- Association between tea consumption and quality of life in men with esophageal squamous carcinoma based on TTD model
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
- Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 59 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
6 hospitals in Fuzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Phase
- Phase 1
- Started
- 2025-08
- Registry
- NCT07391839
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou
- RecruitingTriple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Phase
- Not given
- Started
- 2024-08
- Registry
- NCT06561399
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou
- RecruitingNeoadjuvant Triple Therapy for Resectable HCC
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06569498
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
- RecruitingTriple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Phase
- Not given
- Started
- 2024-09
- Registry
- NCT06602011
Age 18 years to 75 years (registered criteria)
Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led59
- Epigenetic Silencing of SFRP5 Promotes Hepatocellular Carcinoma Progression and Metastasis via Wnt/β-Catenin Signaling.
- Decision Fusion Model for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Multi-MR Habitat Imaging and Machine-Learning Classifiers.
- Percutaneous MR-Guided Thermal Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma.
- Predicting Microvascular Invasion and Early Recurrence in Hepatocellular Carcinoma Using DeepLab V3+ Segmentation of Multiregional MR Habitat Images.
- Single-cell and bulk transcriptome analysis unveils a ligand-receptor-based signature for prognostication and reveals that TREM1 controls the malignant behaviors of hepatocellular carcinoma.
- Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study.
- Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution.
- HRAS Induces Ferroptosis through Upregulating HSPB1 in Hepatocellular Carcinoma.
- CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics.
- Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma.
- E2F2/MUC1 Enhances Cell Stemness of Hepatocellular Carcinoma by Regulating the Notch Signaling Pathway.
- Tumor suppressor OSR1 is modified by SUMO1 and regulates the Wnt/β-catenin signaling pathway in HCC.
- Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression.
- The diagnostic value of hepatitis B core-related antigen in occult hepatitis B virus infection and its related hepatocellular carcinoma.
- Predictive Value of Peripheral Blood Follicular Helper T Cells for Short-term Prognosis in Patients with Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
- An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization.
- The Efficacy and Safety of TACE or HAIC Combined With ICIs and Angiogenesis Inhibitors in Unresectable Hepatocellular Carcinoma.
- A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
- A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model.
- MR-Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma.
- Computed tomography radiomics prediction of survival in hepatocellular carcinoma and is associated with ADH1A expression of the retinol metabolism pathway.
- Construction and validation of a novel model for guiding targeted combined immunotherapy in advanced hepatocellular carcinoma.
- Machine learning analysis identified NNMT as a potential therapeutic target for hepatocellular carcinoma based on PCD-related genes.
- Delta-radiomics Analysis Based on Multi-phase Contrast-enhanced MRI to Predict Early Recurrence in Hepatocellular Carcinoma After Percutaneous Thermal Ablation.
- Prognostic value of FDX1, the cuprotosis key gene, and its prediction models across imaging modalities and histology.
- A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma.
- Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants.
- Long non-coding RNAFOXD1-AS1 modulated CTCs epithelial-mesenchymal transition and immune escape in hepatocellular carcinoma in vitro by sponging miR-615-3p.
- Detection of serum large and middle hepatitis B virus surface proteins: A novel potential diagnostic and prognostic biomarker for chronic hepatitis B.
- ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism.
- Monocyte distribution width as a promising biomarker for differential diagnosis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
- Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- Clinical-Radiologic Morphology-Radiomics Model on Gadobenate Dimeglumine-Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation.
- The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
- Novel nomograms based on microvascular invasion grade for early-stage hepatocellular carcinoma after curative hepatectomy.
- Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.
- LI-RADS category 3, 4, and M observations: a multiple parameters diagnostic model for hepatocellular carcinoma.
- Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients.
- Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
- The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification.
- The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.
- Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma.
- ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.
- Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.
- Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation.
- Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma.
- Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression.
- The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
- Emerging role of mitochondria in response to HBV infection.
- A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma.
- Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.
- Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma.
- A radiomics nomogram based on contrast-enhanced MRI for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma.
- Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma.
- FAM83G promotes proliferation, invasion, and metastasis by regulating PI3K/AKT signaling in hepatocellular carcinoma cells.
- IL-17 and IL-21 polymorphisms in relation to HBV related hepatocellular carcinoma in Chinese Han population.
- Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma.
- [Retracted] Anticancer and apoptotic activities of oleanolic acid are mediated through cell cycle arrest and disruption of mitochondrial membrane potential in HepG2 human hepatocellular carcinoma cells.
- Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status12
- A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
- MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
- Neoadjuvant Triple Therapy for Resectable HCC
- Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
- Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver Cancer
- Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Cancer
Stomach cancer
胃癌Led 38 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.
- Open trials as a site
- 0
- led by another institution
5 hospitals in Fuzhou for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
- Phase
- Phase 2
- Started
- 2024-06
- Registry
- NCT06791083
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led38
- Deciphering the Risk of Developing Lung Cancer after the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysis.
- Short-term and long-term efficacy of laparoscopic D2 lymphadenectomy combined with complete mesogastrium excision for locally advanced upper gastric cancer.
- Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study.
- Dual-layer spectral detector CT-based scoring system for noninvasive TP53 expression assessment and adjuvant chemotherapy response prediction in gastric cancer: a multicenter cross-sectional study.
- Taichunamide-A Inhibits Stomach Cancer Growth Through AKT/MAPK Pathway Suppression and EGFR Inhibitor Synergy.
- Novel m5C-dependent post-transcriptional regulation of KIF11 drives lymphatic metastasis in gastric cancer.
- YY1-mediated transcriptional regulation of LINC01615 inhibits WNT2 mRNA degradation to promote gastric cancer progression.
- PPM1B degradation mediated by TRIM25 ubiquitination modulates cell cycle and promotes gastric cancer growth.
- New classification of gastric polyps: An in-depth analysis and critical evaluation.
- ASO Author Reflections: A Multicenter Retrospective Study on the Clinical and Prognostic Value of Tumor Deposits in Advanced Gastric Cancer.
- Correlation Analysis Between Tumor Deposit and Clinicopathologic Characteristics and Prognosis of Gastric Cancer: A Multicenter Retrospective Study.
- The effect of supplementary parenteral nutrition with different energy intakes on clinical outcomes of patients after gastric cancer surgery.
- Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer.
- NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression.
- Comments on "Novel strategy of hold-and-drag clip closure with mantis-like claw for post-gastric endoscopic submucosal dissection defect of <30 mm".
- Bioinformatics Analysis Reveals Prognostic Significance of the Macrophage Marker Gene Signature in Gastric Adenocarcinoma.
- The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
- Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.
- Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer.
- Integrated bioinformatics analysis for conducting a prognostic model and identifying immunotherapeutic targets in gastric cancer.
- Evaluation of vital genes correlated with CD8 + T cell infiltration as prognostic biomarkers in stomach adenocarcinoma.
- Sex-specific disparities of serum pepsinogen I in relation to body mass index.
- Impact of PIWIL1 Single Nucleotide Polymorphisms on Gastric Cancer Risk in a Chinese Population.
- Association of Malnutrition Diagnosed Using Global Leadership Initiative on Malnutrition Criteria with Severe Postoperative Complications After Gastrectomy in Patients with Gastric Cancer.
- Pretreatment controlling nutritional status (CONUT) score and carcinoembryonic antigen level provide tumor progression and prognostic information in gastric cancer: A retrospective study.
- The short- and long-term effect of laparoscopic total gastrectomy in D2 radical treatment combined with spleno-pancreatectomy under membrane anatomy.
- The short- and long-term effect of membrane anatomy-guided laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision for locally advanced gastric cancer.
- Short and Long-term Efficacy of 3-dimensional Laparoscopic-assisted D2 Radical Gastrectomy Under the Guidance of Membrane Anatomy for Locally Advanced Gastric Cancer.
- Transcriptome sequencing and miRNA-mRNA network construction in exosome of macrophage M2 in stomach adenocarcinoma.
- Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study.
- The effects of nutritional support team intervention on postoperative immune function, nutritional statuses, inflammatory responses, clinical outcomes of elderly patients with gastric cancer.
- [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT.
- Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis.
- Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
- Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT.
- Genetic variants of autophagy-related genes in the PI3K/Akt/mTOR pathway and risk of gastric cancer in the Chinese population.
- Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use.
- Effect of single-incision laparoscopic distal gastrectomy guided by ERAS and the influence on immune function.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status5
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
- A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Fuzhou for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 13 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Fuzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led13
- Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways.
- The integrin α2-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma.
- Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway.
- Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways.
- Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
- Generation and characterization of patient-derived xenografts from patients with osteosarcoma.
- Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.
- Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.
- KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
- MicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4.
- Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways.
- Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.
- Clinicopathological and prognostic value of NADPH oxidase 2 (NOX2) in primary osteosarcoma.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)12
- HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.
- Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma.
- Synthesis and Application of a Long-Circulating Radiolabeled Peptide for Targeting of Osteosarcoma.
- ACTN4 Promotes the Proliferation, Migration, Metastasis of Osteosarcoma and Enhances its Invasive Ability through the NF-κB Pathway.
- [Treatment and influencing factors of infection after limb salvage surgery for malignant tumor around knee joint].
- A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
- Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma.
- Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.
- miR-219a-5p represses migration and invasion of osteosarcoma cells via targeting EYA2.
- Comparative proteomics of cancer stem cells in osteosarcoma using ultra-high-performance liquid chromatography and Orbitrap Fusion mass spectrometer.
- Transdifferentiation of human MNNG/HOS osteosarcoma cells into vascular endothelial cells in vitro and in vivo.
- Verification of TREX1 as a promising indicator of judging the prognosis of osteosarcoma.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
6 hospitals in Fuzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEfficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Registry
- NCT07379047
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
- Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study.
- A novel prognostic system for locally advanced gastrointestinal stromal tumors after neoadjuvant imatinib therapy based on the metro-ticket paradigm: a retrospective dual-center study.
Cancer
Neuroblastoma
神经母细胞瘤Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Fuzhou for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- DDX3X promotes ILF3 stability to accelerate neuroblastoma progression via M2 macrophage polarization.
- Tyramine-enzyme conjugate repeats for an interdigitated capacitance immunosensing array in the detection of neuroblastoma biomarker neuron-specific enolase.
- LINC00460 promotes neuroblastoma tumorigenesis and cisplatin resistance by targeting miR-149-5p/DLL1 axis and activating Notch pathway in vitro and in vivo.
- Competing endogenous RNA network analysis of the molecular mechanisms of ischemic stroke.
- Transcription Factor FOXO3a Overexpression Inhibits the Progression of Neuroblastoma by Regulating the miR-21/SPRY2/ERK Axis.
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 15 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.9%.
2 hospitals in Fuzhou for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingValue of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- Phase
- Early phase 1
- Started
- 2020-08
- Registry
- NCT04504526
Age 18 years to 80 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
- RecruitingA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07477587
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou
- RecruitingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Started
- 2024-05
- Registry
- NCT06375044
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led15
- Global burden and trends of multiple myeloma attributable to high body mass index: a comprehensive analysis of the global burden of disease 2021 study with projections to 2040.
- The value of multiparametric functional MRI histogram features in assessing multiple myeloma activity.
- B4GALT3 as a Key Glycosyltransferase Gene in Multiple Myeloma Progression: Insights From Bioinformatics, Machine Learning, and Experimental Validation.
- Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
- NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway.
- [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.
- Role of BACH1 in multiple myeloma.
- SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.
- Retrospective Analysis of the Expression of CD56 in Multiple Myeloma with Bone-Related Extramedullary Diseases.
- Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.
- NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.
- Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
- NBR2/miR-561-5p/DLC1 axis inhibited the development of multiple myeloma by activating the AMPK/mTOR pathway to repress glycolysis.
- Pathophysiological role of calcium channels and transporters in the multiple myeloma.
- Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status4
- Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病2 hospitals in Fuzhou for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingClinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
- Phase
- Phase 1
- Started
- 2026-05
- Registry
- NCT07491263
Age 14 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Fuzhou for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)5
- [Genotype Analysis of Pregnant Women with α- and β- Thalassemia in Fuzhou Area of Fujian Province in China].
- [Analysis of Gene Mutation Types of Thalassemia in Quanzhou Area of Fujian Province in China].
- [Genotyping of Patients with α and β Thalassemia in Fujian Province Area in China].
- [Epidemiological Survey of Thalassemia in Women of childbearing age in Quanzhou Area of Fujian Province in China].
- [Analysis of Gene Mutation Types of Thalassemia in Longyan Area of Fujian Province in China].
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 4 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
1 hospital in Fuzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study.
- The relationship between plasma prolactin levels and clinical manifestations with neuromyelitis optica spectrum disorders.
- Editorial: Next generation B cell targeting therapies in autoimmune diseases.
- Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder.
All its trials on ClinicalTrials.gov, any status3
Other diseases
Myasthenia gravis
重症肌无力Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Fuzhou for myasthenia gravis89 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 3 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.5%.
- Open trials as a site
- 0
- led by another institution
1 hospital in Fuzhou for Wilson disease28 hospitals in China for Wilson disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Registered Cohort Study on Wilson's Disease
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04012658
Age not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led3
- Altered cortical functional networks in Wilson's Disease: A resting-state electroencephalogram study.
- Reversible Diffusion-Weighted Imaging High Intensity Signal in Wilson Disease.
- Higher Concentration of Plasma Glial Fibrillary Acidic Protein in Wilson Disease Patients with Neurological Manifestations.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Fuzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Fuzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 6 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.8%.
- Open trials as a site
- 0
- led by another institution
4 hospitals in Fuzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Registered Cohort Study on Amyotrophic Lateral Sclerosis
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04008329
Age not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Research advances in dysphagia animal models.
- Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis.
- Detection of pTDP-43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis.
- Alterations in nasal microbiota of patients with amyotrophic lateral sclerosis.
- Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.
- Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis.
Earlier papers (2016–2020)4
- Promoting identification of amyotrophic lateral sclerosis based on label-free plasma spectroscopy.
- Identification and functional analysis of novel mutations in the SOD1 gene in Chinese patients with amyotrophic lateral sclerosis.
- Prognostic analysis of amyotrophic lateral sclerosis based on clinical features and plasma surface-enhanced Raman spectroscopy.
- High frequency of the TARDBP p.M337 V mutation among south-eastern Chinese patients with familial amyotrophic lateral sclerosis.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症2 hospitals in Fuzhou for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Registered Cohort Study on SMA
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04010604
Age 1 week to 70 years (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Earlier papers (2016–2020)3
All its trials on ClinicalTrials.gov, any status3
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 5 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 2.4%.
- Open trials as a site
- 0
- led by another institution
3 hospitals in Fuzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Registered Cohort Study on Duchenne Muscular Dystrophy
- Phase
- Not given
- Started
- 2019-07
- Registry
- NCT04012671
Age 2 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- enOsCas12f1-mediated exon skipping for Duchenne muscular dystrophy therapy in humanized mouse model.
- Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model.
- CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.
- Generation and characterization of an induced pluripotent stem cell line (FJMUNi001-A) from a patient with Duchenne muscular dystrophy carrying c.4518 + 512 T > A variant in the DMD gene.
- Establishment of a human iPSC line XMDYYYi001-A from a patient with Becker muscular dystrophy harboring duplications of exons 2-19 in dystrophin gene.
Earlier papers (2016–2020)2
Other diseases
Behçet disease
白塞病Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Fuzhou for Behçet disease139 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Fuzhou for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- KLF15 deficiency contributes complement activation and podocyte injury in IgA nephropathy via regulating p300/ NF-κB axis.
- Changes in the spectrum of kidney diseases: a 14-year single-center retrospective renal biopsy study from southeast China.
- Association of time-averaged serum uric acid level with clinicopathological information and long-term outcomes in patients with IgA nephropathy.
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Fuzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value.
- Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Fuzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Clinical Impact of Primary Sclerosing Cholangitis on Outcomes of Inflammatory Bowel Disease Hospitalization: A Propensity Score Matching Analysis of the Nationwide Inpatient Sample.
- Investigating the shared genetic architecture between primary sclerosing cholangitis and inflammatory bowel diseases: a Mendelian randomization study.
Earlier papers (2016–2020)1
Other diseases
Hirschsprung disease
先天性巨结肠Led 2 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Fuzhou for Hirschsprung disease76 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Hereditary angioedema
遗传性血管性水肿Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Fuzhou for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Fuzhou for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
福建医科大学附属第一医院
First Affiliated Hospital of Fujian Medical University
福州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Binhai Campus of the First Affiliated Hospital; First Affiliated Hospital of Xiamen University; Longyan First Affiliated Hospital of Fujian Medical University; Binhai Branch of the First Affiliated Hospital